ACE Inhibitor and Biomarkers - Cardiovascular Update

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

ACE Inhibitor

Biomarkers

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

APRIL 9, 2024

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

ACE Inhibitor

ACE Inhibitor Cancer Biomarkers Heart Failure

Abstract 4134796: Safety of over 1000 consecutive, selected low risk patients with accelerated discharge from a chest pain unit with early generation cardiac troponin use, no cardiac functional or anatomic testing and no clinical risk scores

Circulation

NOVEMBER 11, 2024

Women received more discharge cardiac medications than men: antiplatelet agents, statins, beta blockers, ACE inhibitors, angiotensin II blockers, calcium channel blockers, and nitrates (p=0.0002 - 0.04).Follow-up Length of stay (LOS) in the CPU to discharge was 10.4

Chest Pain

Chest Pain ACE Inhibitor Cardiac Function Coronary Artery Disease

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

Abstract 4134796: Safety of over 1000 consecutive, selected low risk patients with accelerated discharge from a chest pain unit with early generation cardiac troponin use, no cardiac functional or anatomic testing and no clinical risk scores

Webinars

Stay Connected